New depression drug candidate ABX-002 enters Mid-Stage trial
Symptom relief
Recruiting now
This study tests whether adding ABX-002 to a current antidepressant can improve symptoms in adults with moderate to severe major depression. About 230 participants will receive either ABX-002 or a placebo for 6 weeks, with follow-up for up to 6 months. The goal is to see if ABX-0…
Phase: PHASE2 • Sponsor: Autobahn Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC